Latest Regulatory Reviews News

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

Siren Gold’s latest drilling at its Sams Creek Project in New Zealand confirms significant gold mineralisation outside the established Main Zone, highlighting promising expansion potential along the 7km Sams Creek Dyke.

Identitii Limited’s ID8N securities have been reinstated to trading following the close of its recent rights issue and the resolution of a Takeovers Panel application.

Northern Minerals has withdrawn its Extraordinary General Meeting and obtained a court order to defer its 2025 AGM until June 30, 2026, allowing more time for regulatory review. This move supports progress toward a key investment decision for its Browns Range rare earths project.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

Viva Energy Group Limited reported a significant net loss for 2025, driven by retail asset impairments, yet underlying profits and strategic investments signal resilience and a clear path forward.

New Frontier Minerals has identified significant exploration targets across 14 prospects in its NWQ Copper Project, with plans to advance the Big One Deposit towards production.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Viridis Mining and Minerals reports strong infill and exploration drilling results at its Colossus Rare Earth Element Project, underpinning a resource upgrade and enhanced project economics. The company advances feasibility, permitting, and financing towards a Final Investment Decision in Q3 2026.